ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance - PubMed
2 hours ago
- #Cell Cycle Regulation
- #Cancer Immunotherapy
- #Protein Modification
- ZDHHC17-mediated palmitoylation of CDK4 is essential for its interaction with cyclin D1 and subsequent cell cycle progression.
- TRAF6-mediated K11-linked ubiquitination of CDK4 is also required for this process, and disruptions in either modification inhibit CDK4 kinase activity.
- High ZDHHC17 expression correlates with resistance to anti-PD-1 immunotherapy, partly due to CDK4's suppression of PD-L1 expression.
- Combining CDK4 inhibitors with immune checkpoint blockers (ICBs) is proposed as a strategy to overcome ZDHHC17-driven cancers.
- The study identifies the ZDHHC17-TRAF6-CDK4 axis as a potential therapeutic target for cancers with dysregulated cell cycles.